Condition:   Breast Cancer Mortality
Intervention:   Other: Invitation for breast screening
Sponsors:   University of Oxford;   Department of Health, United Kingdom
Not yet recruiting - verified March 2010

Conditions:   Breast Cancer;   Bone Metastases
Intervention:   Drug: Radium-223 chloride (Alpharadin)
Sponsor:   Algeta ASA
Recruiting - verified March 2010

Condition:   HIV Infections
Interventions:   Biological: HIV-v (Low Dose);   Biological: HIV-v (High Dose);   Biological: HIV-v (Control)
Sponsor:   PepTcell Limited
Recruiting - verified February 2010

Conditions:   Blood Coagulation Disorders;   Hemophilia A
Interventions:   Biological: Recombinant Factor VIII (Kogenate PF, BAY81-8973);   Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222);   Biological: Recombinant Factor VIII (Kogenate PF, BAY81-8973);   Biological: Recombinant Factor VIII (Kogenate PF, BAY81-8973)
Sponsor:   Bayer
Recruiting - verified March 2010

Condition:   Factor X Deficiency
Intervention:   Biological: FACTOR X
Sponsor:   Bio Products Laboratory
Not yet recruiting - verified March 2010

Condition:   Macular Degeneration
Interventions:   Device: Epimacular Brachytherapy;   Drug: Ranibizumab
Sponsors:   King's College Hospital NHS Trust;   NeoVista
Recruiting - verified February 2010

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: exenatide once weekly;   Drug: insulin detemir
Sponsors:   Amylin Pharmaceuticals, Inc.;   Eli Lilly and Company
Recruiting - verified December 2009

Conditions:   Asthma;   Pulmonary Disease, Chronic Obstructive
Intervention:   Other: Empty inhalers
Sponsor:   Orion Corporation, Orion Pharma
Recruiting - verified February 2010

Condition:   Pulmonary Disease, Chronic Obstructive
Interventions:   Drug: Tiotropium 18mcg daily;   Drug: Salmeterol 100mcg daily;   Drug: Fluticasone 250mcg daily;   Drug: Fluticasone 125mcg daily;   Drug: Fluticasone 50mcg daily;   Drug: Placebo
Sponsor:   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: INSULIN GLARGINE (HOE901);   Drug: Insulin aspart;   Drug: Insulin Glulisine
Sponsor:   Sanofi-Aventis
Recruiting - verified March 2010

Condition:   Sarcoidosis
Interventions:   Drug: Placebo;   Drug: golimumab;   Drug: ustekinumab
Sponsor:   Centocor, Inc.
Recruiting - verified February 2010

Condition:   Alzheimer's Disease
Interventions:   Drug: LY2062430;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Recruiting - verified March 2010

Condition:   Carcinoma, Hepatocellular
Interventions:   Drug: Sorafenib (Nexavar, BAY43-9006);   Drug: Sorafenib (Nexavar, BAY43-9006) + Erlotinib, Tarceva
Sponsors:   Bayer;   Onyx Pharmaceuticals;   OSI Pharmaceuticals;   Hoffmann-La Roche
Recruiting - verified March 2010

Condition:   Pulmonary Arterial Hypertension
Interventions:   Drug: QTI571;   Drug: Placebo
Sponsor:   Novartis Pharmaceuticals
Recruiting - verified February 2010

Condition:   Breast Cancer
Interventions:   Drug: neratinib;   Other: placebo
Sponsor:   Wyeth
Recruiting - verified March 2010

Condition:   Multiple Sclerosis, Relapsing-Remitting
Interventions:   Drug: Daclizumab HYP;   Drug: Daclizumab HYP
Sponsors:   Biogen Idec;   Facet Biotech
Recruiting - verified March 2010

Condition:   Ovarian Cancer
Interventions:   Drug: MORAb-003 (farletuzumab);   Drug: MORAb-003 (farletuzumab);   Drug: 0.9% Saline
Sponsor:   Morphotek
Recruiting - verified October 2009

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Apixaban;   Drug: Placebo
Sponsors:   Bristol-Myers Squibb;   Pfizer;   Duke University
Recruiting - verified October 2009

Conditions:   Malignant Mesothelioma;   Metastatic Cancer
Interventions:   Other: talc;   Procedure: therapeutic thoracoscopy;   Procedure: therapeutic videothoracoscopy
Sponsor:   Papworth Hospital
Recruiting - verified June 2009

Condition:   Metastatic Breast Cancer
Interventions:   Drug: capecitabine;   Drug: trastuzumab;   Drug: lapatinib
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   ADHD
Interventions:   Drug: SPD489 (lisdexamfetamine dimesylate);   Drug: Placebo
Sponsor:   Shire Pharmaceutical Development
Recruiting - verified March 2010

Condition:   Epilepsies, Partial
Intervention:  
Sponsor:   UCB, Inc.
Recruiting - verified March 2010

Condition:   ADHD
Interventions:   Drug: LDX;   Drug: Methylphenidate Hydrochloride;   Drug: Placebo
Sponsor:   Shire Pharmaceutical Development
Recruiting - verified February 2010

Condition:   Idiopathic Pulmonary Fibrosis
Intervention:   Drug: ambrisentan or sugar pill
Sponsor:   Gilead Sciences
Recruiting - verified March 2010

Condition:   Attention Deficit Hyperactivity Disorder
Intervention:   Drug: Atomoxetine
Sponsor:   Eli Lilly and Company
Recruiting - verified March 2010

Condition:   Type 2 Diabetes
Interventions:   Drug: Saxagliptin;   Drug: Placebo
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Recruiting - verified October 2009

Condition:   Soft Tissue Sarcoma
Intervention:   Drug: PAZOPANIB
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Neuroendocrine Tumors
Intervention:  
Sponsor:   Ipsen
Recruiting - verified February 2010

Condition:   Diabetes Mellitus
Interventions:   Drug: Exubera;   Other: Randomized diabetes therapy
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Locally Advanced and/or Metastatic Renal Cell Carcinoma
Interventions:   Drug: Sunitinib;   Drug: Pazopanib
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Conditions:   Carcinoma, Renal Cell;   Adenocarcinoma, Renal Cell;   Nephroid Carcinoma;   Carcinoma, Hypernephroid
Interventions:   Drug: bevacizumab, RAD001(Everolimus);   Drug: bevacizumab, interferon alfa-2a
Sponsors:   Novartis Pharmaceuticals;   Roche Pharma AG
Recruiting - verified March 2010

Condition:   Thyroid Cancer
Interventions:   Drug: XL184;   Drug: Placebo
Sponsor:   Exelixis
Recruiting - verified March 2010

Conditions:   Hormone Refractory Prostate Cancer;   Bone Metastases
Interventions:   Drug: Alpharadin (Radium-223);   Drug: Placebo
Sponsor:   Algeta ASA
Recruiting - verified March 2009

Conditions:   Diabetic Retinopathy;   Diabetes Complications
Interventions:   Procedure: Laser Treatment;   Drug: PF-04523655 high;   Drug: PF-04523655 middle;   Drug: PF-04523655 low
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Thromboembolism
Interventions:   Drug: Dabigatran etexilate;   Drug: Warfarin
Sponsor:   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010

Condition:   Pulmonary Arterial Hypertension
Intervention:   Drug: ambrisentan
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Kidney Neoplasms
Interventions:   Drug: Axitinib (AG-013736);   Drug: Sorafenib
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Prostatic Neoplasms
Interventions:   Drug: Prednisone;   Drug: sunitinib;   Drug: Placebo;   Drug: Prednisone
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Opioid-induced Constipation
Interventions:   Drug: Methylnaltrexone bromide (MOA-728);   Drug: Placebo
Sponsors:   Wyeth;   Progenics Pharmaceuticals, Inc.
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: trastuzumab;   Drug: docetaxel;   Drug: lapatinib ditosylate;   Drug: paclitaxel;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
Sponsors:   NCIC Clinical Trials Group;   GlaxoSmithKline
Recruiting - verified July 2009

Condition:   Alzheimer Disease
Interventions:   Drug: bapineuzumab;   Drug: placebo
Sponsor:   Wyeth
Recruiting - verified March 2010

Condition:   Multiple Sclerosis
Interventions:   Drug: Teriflunomide (HMR1726);   Drug: Placebo
Sponsor:   Sanofi-Aventis
Recruiting - verified March 2010

Condition:   Venous Thromboembolism
Interventions:   Drug: Xarelto (Rivaroxaban, BAY59-7939);   Drug: Enoxaparin
Sponsors:   Bayer;   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: Trastuzumab;   Drug: Lapatinib
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Tumor Antigen-positive Non-Small Cell Lung Cancer
Interventions:   Biological: GSK1572932A Antigen-Specific Cancer Immunotherapeutic;   Biological: Placebo Control
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: AMG 706;   Drug: placebo
Sponsors:   Amgen;   Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010

Conditions:   Lymphoma;   Neutropenia;   Psychosocial Effects of Cancer and Its Treatment;   Small Intestine Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: amoxicillin-clavulanate potassium;   Drug: ciprofloxacin;   Procedure: psychosocial assessment and care;   Procedure: quality-of-life assessment
Sponsor:   Clatterbridge Centre for Oncology
Recruiting - verified May 2007

Conditions:   Extrahepatic Bile Duct Cancer;   Gallbladder Cancer;   Liver Cancer
Interventions:   Drug: capecitabine;   Other: clinical observation;   Procedure: adjuvant therapy
Sponsor:   Southampton University Hospitals NHS Trust
Recruiting - verified March 2008

Condition:   Endocrine Tumors
Interventions:   Drug: lanreotide (Autogel formulation);   Other: Placebo
Sponsor:   Ipsen
Recruiting - verified March 2010

Conditions:   Ovarian Cancer;   Merkel Cell Carcinoma;   SCLC
Intervention:   Drug: BB-10901
Sponsor:   ImmunoGen, Inc.
Recruiting - verified March 2010

Condition:   Thromboembolism
Interventions:   Drug: Dabigatran;   Drug: Warfarin
Sponsor:   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010

Condition:   Pulmonary Hypertension
Interventions:   Drug: bosentan;   Drug: placebo
Sponsor:   Actelion
Recruiting - verified March 2010

Condition:   Heart Failure
Interventions:   Drug: Eplerenone;   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: exemestane;   Drug: tamoxifen citrate;   Drug: triptorelin;   Procedure: oophorectomy;   Radiation: radiation therapy
Sponsors:   International Breast Cancer Study Group;   National Cancer Institute (NCI);   Breast International Group;   Cancer and Leukemia Group B;   NCIC Clinical Trials Group;   North Central Cancer Treatment Group;   National Surgical Adjuvant Breast and Bowel Project (NSABP);   Southwest Oncology Group
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Biological: dactinomycin;   Drug: busulfan;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: melphalan;   Drug: vincristine sulfate;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   University Hospitals, Leicester;   National Cancer Institute (NCI);   Children's Cancer and Leukaemia Group;   Societe Francaise Oncologie Pediatrique;   European Organization for Research and Treatment of Cancer;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria;   Swiss Group for Clinical Cancer Research;   EBMT Solid Tumors Working Party;   Children's Oncology Group
Recruiting - verified March 2010